() founder and managing director Layton Mills speaks to Proactive Investors about the innovative pet pharmaceutical company, which operates in the medical cannabis space.
"The goal for the company is really to develop products that can address clear, unmet needs in the animal health market, focusing on companion animals. We have a lead drug candidate that's currently in development, that's CPAT-01, which we're developing as a pain control in dogs... we've just finished wrapping up our first Phase 1A Pharmacokinetic and Safety Study, which is a really exciting milestone for the company," says Mills.
CannPal Animal Therapeutics is simultaneously developing nutraceutical products using Cannabidiol, a less regulated cannabinoid than THC and CBD, in order to generate early revenues as the core pharmaceutical products go through the necessary approvals processes.